Fully human antibody against TβRI halts tumor growth and metastasis in preclinical prostate cancer models

Umeå University reports a novel fully human monoclonal antibody that blocks oncogenic signaling through the TGF‑β receptor I (TβRI), producing striking inhibition of both tumor growth and metastatic spread in aggressive prostate cancer models, according to a study published in Signal Transduction and Targeted Therapy. The antibody is composed entirely of human proteins, reducing immunogenicity risk and improving translational potential relative to non‑human biologics.

TGF‑β signaling plays a complex, context‑dependent role in prostate cancer: it can suppress early tumorigenesis but drives invasiveness, epithelial‑to‑mesenchymal transition (EMT), immune suppression, and metastatic niche formation in advanced disease. The Umeå antibody targets oncogenic TβRI signaling and, by preventing downstream effectors implicated in invasion and metastasis, appears to blunt both primary tumor progression and dissemination in androgen‑independent preclinical models. That dual action, reducing proliferative capacity while limiting metastasis, is therapeutically attractive because the principal cause of mortality in prostate cancer is metastatic disease, not localized tumor growth.

According to the authors, the antibody produced robust anti‑tumor activity in models reflective of aggressive, androgen‑independent prostate cancer and reduced metastatic burden in relevant in vivo systems. The study includes mechanistic work demonstrating pathway suppression consistent with TβRI blockade, and the development team reports collaboration with translational drug development experts to optimize the antibody construct and perform initial safety‑focused studies.

Importantly, the preclinical study also reported no noticeable adverse effects on body weight, proximal aorta, or heart function in immune-deficient mice, which is encouraging from a safety standpoint. That matters because TGF-β pathway interventions have often been limited by concerns about systemic toxicity and context-dependent biology, especially in tissues where the pathway plays normal homeostatic roles. By targeting the pathologic cleavage event that generates the prometastatic TβRI intracellular domain, rather than broadly suppressing all TGF-β signaling, this approach may preserve more of the pathway’s normal physiology while still blocking the metastatic program.

If these effects translate to humans, the therapy could address an unmet need in metastatic castration‑resistant prostate cancer (mCRPC) by directly targeting metastasis biology rather than offering only cytoreduction. A well‑tolerated, fully human anti‑TβRI antibody could be used as a single agent in androgen‑independent disease or combined with androgen‑receptor (AR) pathway inhibitors, immune checkpoint inhibitors, or PSMA‑targeted radioligand therapy to augment responses and overcome immune suppression in the tumor microenvironment.

Source.